These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 19514965)

  • 21. Pathophysiological and disease-induced changes in drug distribution volume: pharmacokinetic implications.
    Klotz U
    Clin Pharmacokinet; 1976; 1(3):204-18. PubMed ID: 797498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
    Kharasch ED; Hoffer C; Whittington D; Sheffels P
    Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
    Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
    J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression.
    Fleishaker JC
    Clin Pharmacokinet; 2000 Dec; 39(6):413-27. PubMed ID: 11192474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models.
    Yoshikado T; Maeda K; Kusuhara H; Furihata KI; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2739-2750. PubMed ID: 28495568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing pediatric dosing: a developmental pharmacologic approach.
    Anderson GD; Lynn AM
    Pharmacotherapy; 2009 Jun; 29(6):680-90. PubMed ID: 19476420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Humanizing the zebrafish liver shifts drug metabolic profiles and improves pharmacokinetics of CYP3A4 substrates.
    Poon KL; Wang X; Ng AS; Goh WH; McGinnis C; Fowler S; Carney TJ; Wang H; Ingham PW
    Arch Toxicol; 2017 Mar; 91(3):1187-1197. PubMed ID: 27485346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo evaluation of the effect of puerarin on hepatic cytochrome p450-mediated drug metabolism.
    Kim SB; Yoon IS; Kim KS; Cho SJ; Kim YS; Cho HJ; Chung SJ; Chong S; Kim DD
    Planta Med; 2014 May; 80(7):561-7. PubMed ID: 24710899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals.
    Ginsberg G; Hattis D; Russ A; Sonawane B
    Environ Health Perspect; 2005 Sep; 113(9):1243-9. PubMed ID: 16140636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
    Thummel KE; O'Shea D; Paine MF; Shen DD; Kunze KL; Perkins JD; Wilkinson GR
    Clin Pharmacol Ther; 1996 May; 59(5):491-502. PubMed ID: 8646820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly.
    Turnheim K
    Exp Gerontol; 2003 Aug; 38(8):843-53. PubMed ID: 12915206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug metabolism and ageing.
    Wynne H
    J Br Menopause Soc; 2005 Jun; 11(2):51-6. PubMed ID: 15970015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using pharmacokinetics in drug therapy. VII: Pharmacokinetic factors influencing drug therapy in the aged.
    Schumacher GE
    Am J Hosp Pharm; 1980 Apr; 37(4):559-62. PubMed ID: 6990755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis.
    Le Couteur DG; McLean AJ
    Clin Pharmacokinet; 1998 May; 34(5):359-73. PubMed ID: 9592620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.
    Mei Q; Tang C; Assang C; Lin Y; Slaughter D; Rodrigues AD; Baillie TA; Rushmore TH; Shou M
    J Pharmacol Exp Ther; 1999 Nov; 291(2):749-59. PubMed ID: 10525096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative pharmacokinetic changes and drug therapy in an older population.
    Lamy PP
    J Am Geriatr Soc; 1982 Nov; 30(11 Suppl):S11-9. PubMed ID: 6752251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of novel substrates for human cytochrome P450 2J2.
    Lee CA; Neul D; Clouser-Roche A; Dalvie D; Wester MR; Jiang Y; Jones JP; Freiwald S; Zientek M; Totah RA
    Drug Metab Dispos; 2010 Feb; 38(2):347-56. PubMed ID: 19923256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
    Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
    Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data.
    Gertz M; Harrison A; Houston JB; Galetin A
    Drug Metab Dispos; 2010 Jul; 38(7):1147-58. PubMed ID: 20368326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.